Aclaris Therapeutics Inc (ACRS) has experienced challenges in growth. The company operates in the Healthcare sector, specifically in the Biotechnology industry.
Over the past 4 years, Aclaris Therapeutics Inc has achieved a revenue compound annual growth rate (CAGR) of 30.4%, while earnings have grown at 26.8% CAGR.
Historical revenue and profitability trends for Aclaris Therapeutics Inc
The chart above illustrates Aclaris Therapeutics Inc's revenue trajectory over the past 4 years. The revenue pattern shows the challenges the company has faced in recent periods.
Annual percentage change in revenue and earnings
Growth rates provide insight into the momentum of Aclaris Therapeutics Inc's business.
How efficiently Aclaris Therapeutics Inc converts revenue into profit
Profit margins reveal how much of each dollar of revenue Aclaris Therapeutics Inc retains at different stages:
Analyst estimates and forward-looking indicators
Wall Street analysts project Aclaris Therapeutics Inc to continue focusing on sustainable operations. The consensus analyst rating is 4.3333 based on 6 analysts.
Based on our comprehensive analysis, Aclaris Therapeutics Inc (ACRS) demonstrates declining growth characteristics.
This growth analysis provides a comprehensive view of Aclaris Therapeutics Inc's historical performance and future outlook. Investors should consider these growth metrics alongside valuation, competitive positioning, and broader market conditions when making investment decisions. Past performance does not guarantee future results.
See how Aclaris Therapeutics Inc stacks up against similar companies
Explore growth analysis for top stocks
Related: ACRS Valuation, ACRS Dividend, ACRS Financial Health
Compare: ACRS vs AAPL, ACRS vs MSFT, ACRS vs GOOGL